Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

Study summary

A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedNivolumab

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 5, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?17 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Bristol-Myers Squibb
Interventions being studied: Biological: Nivolumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Metastatic or stage IV→

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Non small cell lung cancer (Squamous or non-squamous)
At least one prior anti-cancer therapy that did not work
ECOG Performance Scale 0-1

Reasons someone may not be able to joinExclusion criteria

Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug
Active, known or suspected autoimmune disease or infection
Prior immuno-oncology therapy
Corticosteroids within 2 weeks of study drug administration Other protocol defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Alabama OncologyBirmingham, Alabama
Los Angeles Hematology Oncology Medical GroupLos Angeles, California
St Vincent Frontier Cancer CenterBillings, Montana
Broome OncologyJohnson City, New York
Guthrie Medical Group SayreSayre, Pennsylvania
Local Institution - 0015Kingston, Ontario
Local Institution - 0014Oshawa, Ontario
Local Institution - 0001Toronto, Ontario
Local Institution - 0017Nagoya, Aichi-ken
Local Institution - 0023Osaka, Osaka
Local Institution - 0018Koto-ku, Tokyo
Local Institution - 0016Tokyo

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 5, 2022. Always confirm current availability with the study team.

View original record ↗